The city of Charleston, South Carolina, currently has 10 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Medical University of South Carolina-Nexus, Charleston, South Carolina
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
06/13/2024
Locations: Medical University of South Carolina- College of Medicine, Charleston, South Carolina
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
All
Ages:
21 years and above
Trial Updated:
06/13/2024
Locations: Medical University of South Carolina- College of Medicine, Charleston, South Carolina
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
NCT06097260
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
06/11/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
NCT05671835
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
06/06/2024
Locations: The Medical University of South Carolina, Charleston, South Carolina
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
NCT04708782
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
06/04/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates
To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF
NCT05483907
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and tolerability of 200 mg twice daily (BID) of BBT-877 in patients with IPF, with or without AF approved background therapies (pirfenidone or nintedanib).
Gender:
All
Ages:
40 years and above
Trial Updated:
05/28/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Lowcountry Lung and Critical Care, Charleston, South Carolina
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
NCT05389215
Recruiting
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Gender:
All
Ages:
40 years and above
Trial Updated:
04/16/2024
Locations: The U.S. Department of Veterans Affairs, Charleston, South Carolina +1 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
NCT01915511
Recruiting
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progre... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
04/09/2024
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Register for Updates